Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 6/20 | 0.55 |
| ▸ | ATR | Q13535 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 12/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | FECH | P22830 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | MELK | Q14680 | 1/20 | 0.50 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 0.50 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.50 |
| ▸ | TP53RK | Q96S44 | 1/20 | 0.50 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.46 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994768 | 0.91 | MTOR (0.51) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL927889 | 0.87 | ATM (0.58) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL929984 | 0.86 | MTOR (0.62) | ATMATRMTORPIK3CAPIK3CD | |
| SCHEMBL928350 | 0.86 | ATM (0.58) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL927875 | 0.86 | ATM (0.58) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL9904995 | 0.84 | ATM (0.52) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL928971 | 0.83 | MTOR (0.56) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL31439384 | 0.83 | MTOR (0.56) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL9905138 | 0.83 | MTOR (0.58) | ATMATRKCNH2MTORPIK3CA | |
| SCHEMBL930601 | 0.82 | MTOR (0.65) | ATMATRKCNH2MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | claimed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | claimed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | claimed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | claimed |
| US-9370508-B2 | Imidazoquinolines as dual lipid kinase and mTOR inhibitors | NOVARTIS AG (CH) | 2016-06-21 | — | — | US | disclosed |
| EP-2624831-A1 | PHARMACEUTICAL COMBINATIONS | Novartis AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2013-07-11 | — | — | US | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | NOVARTIS AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| EP-2129379-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS | Novartis AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009118324-A1 | 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008103636-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | ATM 1665/4885ATR 3330/4885KCNH2 1871/4885 |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | MTOR, RICTOR, PIK3CA | ATM 545/4885ATR 725/4885KCNH2 4207/4885 |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | KDR, FLT4, TEK | ATM 3879/4885ATR 3288/4885KCNH2 3766/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | ATM 1665/4885ATR 3330/4885KCNH2 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.